Cimetidine
Brand names: Tagamet
Cimetidine is a histamine H2-receptor antagonist used to reduce gastric acid secretion in conditions such as peptic ulcer disease, gastro-oesophageal reflux and dyspepsia.
Adult dose
Paediatric dose
Dose adjustments
Reduce the dose according to creatinine clearance (SPC §4.4): CrCl 0-15 mL/min — 200 mg twice a day; 15-30 mL/min — 200 mg three times a day; 30-50 mL/min — 200 mg four times a day; over 50 mL/min — normal dosage. Cimetidine is removed by haemodialysis but not to any significant extent by peritoneal dialysis.
Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.
Contraindications
- Hypersensitivity to the active substance or to any of the excipients
Side effects
- Headache and dizziness (common)
- Diarrhoea (common)
- Skin rashes (common)
- Myalgia and tiredness (common)
- Gynaecomastia and reversible impotence (uncommon)
- Confusional states, depression, hallucinations (uncommon) — usually in elderly or ill patients, reversible within a few days of withdrawal
Interactions
- Cimetidine can prolong the elimination of drugs metabolised by oxidation in the liver (e.g. diazepam, propranolol)
- Oral anticoagulants / coumarins — close monitoring of prothrombin time recommended; dose reduction may be necessary
- Phenytoin — close monitoring recommended; dose reduction may be necessary
- Theophylline — dosage adjustment may be required when starting or stopping cimetidine
- Intravenous lidocaine (lignocaine) — clinically significant interaction
- Drugs with a narrow therapeutic index generally — absorption, metabolism or renal excretion may be affected, needing dose adjustment or discontinuation
- Drug treatments or illnesses that could cause falls in blood cell count — H2-receptor antagonism could potentiate this effect
Clinical monograph
How it works
It competitively blocks histamine H2 receptors on gastric parietal cells, reducing both basal and stimulated gastric acid secretion.
Prescribing in practice
- Cimetidine is a potent inhibitor of several cytochrome P450 enzymes and raises plasma concentrations of many drugs, including warfarin, phenytoin and theophylline, so co-prescribing requires careful review and dose adjustment.
- Doses should be reduced in renal impairment, and it can cause confusion in elderly or seriously ill patients.
- Acid suppression may mask the symptoms of gastric cancer, so alarm features should be investigated before attributing them to benign dyspepsia.
Monitoring
Routine laboratory monitoring is not required, but monitor the effects of interacting drugs, such as the INR in patients taking warfarin, and review renal function where relevant.
Counselling the patient
- Tell your prescriber about all your other medicines, as interactions are common.
- Report any persistent difficulty swallowing, weight loss or signs of bleeding.
- Let your team know if you feel confused, particularly if you are elderly or unwell.
Evidence & guidelines
H2-receptor antagonists are an established acid-suppressing option for peptic ulcer disease and reflux, though proton pump inhibitors are generally preferred first-line in NICE guidance.
Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Lower Gastrointestinal Bleed · BSG 2019; NICE NG141
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021